Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Maternal mortality highlighted Americas' need for wider healthcare cover

This article was originally published in Clinica

Executive Summary

The Pan American Health Organization (PAHO) is calling for national health policies to better address the need to expand medical coverage among indigenous communities, particularly in light of the high rates of infant and maternal mortality among these. The latest edition of its bulletin on indigenous health - Healing our Spirit Worldwide - notes that national averages can mask significant regional variations in these rates. In Bolivia, for example, maternal mortality stands nationally at 390 per 100,000 live births, but in the department of Potosi, home to a large indigenous population, the rate is 496. Similarly, the Honduran departments of Colon, Copan, Intibuca, Lempira and La Paz have maternal mortality rates ranging from 190 to 255 per 100,000 live births, compared with a national average of 147. In Guatemala, maternal mortality is 83% higher among indigenous women than the national rate.

You may also be interested in...



Lilly’s ‘High Quality’ Donanemab Data Supports Unrestricted Medicare Coverage, Firm Says

As FDA decision on Alzheimer’s product approaches, new paper outlines Lilly’s arguments for unfettered Medicare coverage for donanemab once it is approved.

Oncopeptides’ Pepaxto Withdrawal Speeds Through In 7 Months Under Expedited Procedures

Of three accelerated approval drugs that have been ordered withdrawn to date, Pepaxto marks the shortest interval between the FDA drugs center's withdrawal proposal and the agency’s final order, suggesting that FDORA’s expedited withdrawal procedures helped move things along more quickly.

Accelerated Approval: US FDA’s Hammer Falls On Oncopeptides’ Pepaxto

Rejecting company’s appeal, CBER Director Peter Marks says the multiple myeloma drug should be withdrawn because its confirmatory trial failed to verify clinical benefit and evidence demonstrates the drug is not safe and effective for its current indication.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT059025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel